Gynecologic Oncology Articles

Wingo Weighs in on Surgical Approaches in Ovarian Cancer
Shana Wingo, MD, discusses the surgical landscape in patients with newly diagnosed ovarian cancer.
Treatment Approaches Evolving in Recurrent Ovarian Cancer
Dennis R. Scribner Jr, MD, discusses the elements and evolution of treatment for patients with recurrent ovarian cancer.
Genetic Testing Becoming More Widespread in Ovarian Cancer, But Challenges Remain
Mike Janicek, MD, discusses the importance of genetic testing and how the ovarian field can benefit from a better understanding of it through genetic counselors and self-education.
Expert Shares Intriguing Ovarian Cancer Cases, Highlights Individualized Treatment
Matthew Borst, MD, highlights the need for neoadjuvant therapy versus upfront surgery in newly diagnosed patients, effective treatment management for recurrent platinum-sensitive disease, and what to do in the third-line setting and beyond.
Frontline Treatment in Ovarian Cancer Could Undergo Transformation
Heather Dalton, MD, discusses the developing standard of care for the frontline treatment of patients with ovarian cancer.
Expert Encourages Widespread Use of ERAS in Ovarian Cancer
Snehal Bhoola, MD, discusses the implementation of enhanced recovery after surgery in ovarian cancer.
Olaparib Tablets Approved in Europe for Ovarian Cancer, Regardless of BRCA Status
The European Commission has approved olaparib tablets (Lynparza) as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube or primary peritoneal cancer. 
Rucaparib FDA Approval Creates Trifecta of Maintenance PARP Inhibitors in Ovarian Cancer
Lyndsay Willmott, MD, discusses the use of PARP inhibitors in patients with ovarian cancer and details the mechanisms of resistance that have been identified so far.
Monk Highlights Clinical Trials in Recurrent Ovarian Cancer
Bradley J. Monk, MD, FACOG, FACS, discusses the promise of new therapies and regimens in patients with ovarian cancer in the recurrent setting.
Niraparib Active in Heavily Pretreated Ovarian Cancer, Regardless of BRCA Status
Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA status, according to top-line results from the QUADRA study.
Publication Bottom Border
Border Publication